Contineum Therapeutics

Pipeline Therapeutics is a biotechnology company focused on developing next-generation neuro-regenerative therapies. Located near the University of California, San Diego, the company operates in the biopharmaceutical sector, targeting neurological disorders such as hearing loss, multiple sclerosis (MS), and other synaptopathies and demyelinated diseases. Pipeline Therapeutics serves patients and healthcare providers by advancing first-in-class therapeutics aimed at synaptogenesis (the formation of synapses), remyelination (the repair of myelin sheaths around nerves), and axonal repair (restoring function in damaged axons). The business model revolves around research and development (R&D) of small molecules and biologics, which are then licensed or sold to larger pharmaceutical companies or brought to market through strategic partnerships. Revenue is generated through licensing agreements, milestone payments, and royalties from commercialized products. The company is led by Carmine Stengone, President and CEO, and Daniel Lorrain, PhD, Chief Scientific Officer, both of whom bring extensive experience in biotech and pharmaceutical development.

Keywords: neuro-regenerative, synaptogenesis, remyelination, axonal repair, biotechnology, neurological disorders, small molecules, biologics, R&D, licensing.